Description
The ProbeSeq Programmed Death-Ligand 1 (PD-L1 / CD274) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human PD-L1, an immune checkpoint protein that regulates T-cell activity and tumor immune escape. This nanobody supports research-use assay development, cancer immunotherapy studies, and advanced biosensor integration.
PD-L1 is widely recognized as a clinically relevant biomarker for immune checkpoint inhibitor therapy selection and monitoring. Expression of PD-L1 on tumor cells and immune cells is associated with response to anti-PD-1/PD-L1 therapies across multiple cancer types. Sensitive detection of PD-L1 is critical for immuno-oncology research, tumor microenvironment profiling, and development of rapid cancer diagnostic technologies.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and high structural stability. Compared with conventional antibodies, nanobodies offer superior thermal stability, enhanced tissue penetration, and efficient surface immobilization, enabling high-performance detection in electrochemical sensors, microfluidic devices, and miniaturized diagnostic systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cell lysates, extracellular vesicles, and tumor-derived samples following appropriate assay optimization.
What’s Included
Recombinant anti-PD-L1 single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request.
Target Strategy
Engineered for high binding specificity to PD-L1 extracellular domain epitopes
Minimal cross-reactivity with related immune checkpoint proteins
Stable binding under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request.
Performance Orientation
Electrochemical biosensors
Immuno-oncology assay development
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care cancer diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request.
Applications
Cancer immunotherapy response research
Immune checkpoint profiling studies
Tumor microenvironment analysis
Immunoassay and biosensor development
Liquid biopsy research
Microfluidic diagnostic platform integration
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
